{"entity":{"id":"nct02332668","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab in melanoma and hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) is a phase 1/2 interventional study registered as NCT02332668 by Merck Sharp & Dohme LLC, with 370 participants planned, started 2015-03-19 and due to reach its primary completion in 2028-02-02. Interventions recorded: Pembrolizumab. Conditions listed: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02332668","url":"https://clinicaltrials.gov/study/NCT02332668"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02332668","phase":"1/2","setting":"A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)","sponsor":"Merck Sharp & Dohme LLC","enrolled":370,"outcomes":[]},"route":"/trials/nct02332668/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}